Abstract
Overview
Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that
affects the gastrointestinal tract causing a number of distressing symptoms
such as bleeding, diarrhea and abdominal pain. IBD includes key subsets
Crohn' s disease and ulcerative colitis, both of which can significantly impact
on the quality of life of an individual.
Scope
- Analysis of the inflammatory bowel disease market based on a survey of 180
gastroenterologists supported by key opinion leader interviews
- Overview of epidemiology and patient segmentation in IBD
- Influences on gastroenterologists' prescribing behavior and their
perception of current brands such as Remicade, Humira, Pentasa, Asacol and
Lialda
- Assessment of outcomes of treatment with Remicade focusing on treatment
failure and reasons for failure
Highlights
Clinical guidelines recommend a step-up treatment approach. However,
Datamonitor' s survey suggests that currently 20% of patients with severe IBD
currently receive an early aggressive treatment approach. There is an ongoing
debate among Gastroenterologists and Datamonitor believe this approach will
become more commonplace in the future.
Remicade remains the first choice biologic therapy in 80% of biologic-naïve
patients. However, Humira has distinct advantages over Remicade that will lead
to strong. Humira is positioned as a treatment for Remicade-failure patients,
but Datamonitor' s survey suggests currently only 30% of these patients go on
to receive Humira.
Shire' s Lialda (mesalazine), recently launched as a once-daily drug, is
perceived by gastroenterologists to perform well on patient compliance. In a
drug class where there is little differentiation between brands over efficacy
and safety, Lialda will provide a clinical advantage thanks to its improved
dosing regimen.
Reasons to Purchase
- Target prescribers more effectively, through an understanding of
prescribing behavior and influencing factors
- Validate new product forecasting based on diagnosis and treatment rates,
and the likely rate of uptake for new products
- Benchmark brand awareness and perceptions surrounding product positioning
in order to formulate competitive lifecycle management strategies
| 
View Cart
